4 Papers
2 Citations
S Ali is an academic researcher from Pennine Acute Hospitals NHS Trust. The author has contributed to research in topics: Endometrial cancer & Insulin resistance. The author has an hindex of 3, co-authored 4 publications. Previous affiliations of S Ali include Manchester Academic Health Science Centre & Royal Oldham Hospital.
Chat about Author
Papers
PRE-surgical Metformin In Uterine Malignancy (PREMIUM): a Multi-Center, Randomized Double-Blind, Placebo-Controlled Phase III Trial.
Sarah Kitson,Zoe Maskell,Vanitha N Sivalingam,Jennifer L. Allen,S Ali,S Ali,Sean Burns,Kyle Gilmour,Rahamatulla Latheef,Richard J Slade,Philip W. Pemberton,Joseph Shaw,W David J Ryder,Henry C Kitchener,Emma J Crosbie,Emma J Crosbie +15 more
TL;DR: Short-term treatment with standard diabetic doses of metformin does not reduce tumor proliferation in women with endometrioid endometrial cancer awaiting hysterectomy and casts doubt on its potential application in the primary and adjuvant treatment settings.
Pre-surgical window study of metformin in obesity-driven endometrial cancer
Vanitha N Sivalingam,Rhona J McVey,Sarah Kitson,Kyle Gilmour,S Ali,Chris Roberts,Andrew G Renehan,Henry C Kitchener,Emma J Crosbie +8 more
TL;DR: RNA sequencing analysis of treated and untreated PDX tumors demonstrated that numerous factors with roles in ribosomal synthesis were significantly altered by treatment, offering a novel opportunity to specifically target the chemoresistant population in ovarian cancer.
4
A presurgical window-of-opportunity study of metformin in obesity-driven endometrial cancer
Vanitha N Sivalingam,Rhona J McVey,Kyle Gilmour,S Ali,Chris Roberts,Andrew G Renehan,Henry C Kitchener,Emma J Crosbie +7 more
TL;DR: The hypothesis that metformin would reduce cellular proliferation in vivo in atypical endometrial hyperplasia and endometrioid adenocarcinoma by inducing phosphorylation of AMP-activated kinase and subsequent mTOR proproliferative inhibition, independent of insulin and insulin-like growth factor receptor activation is explored.
Measuring the biological effect of presurgical metformin treatment in endometrial cancer
Vanitha N Sivalingam,Sarah Kitson,Rhona J McVey,Chris Roberts,Philip W. Pemberton,Kyle Gilmour,S Ali,Andrew G Renehan,Henry C Kitchener,Emma J Crosbie +9 more
TL;DR: Short-term metformin was associated with reduced Ki-67 expression in EC and changes in tumour PI3K-AKT-mTOR protein phosphostatus were seen in both groups.